Boustead Singapore's (SGX:F9D) real estate solutions division business secured a major design-and-build contract for an integrated pharmaceutical manufacturing and R&D facility situated within Tuas Biomedical Park, Singapore, according to a Friday filing with the Singapore Exchange.
The project is expected to complete by the third quarter of 2026 and takes the real estate solutions division's order backlog to SG$249 million and the group's engineering order backlog to SG$428 million, the filing said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。